Our Team
Tom Barnes
CEO & BOARD MEMBER
Dr Thomas M. Barnes has served as CEO and board member of Averna Therapeutics since 2025. He was previously CEO of Orna Therapeutics, where he led Series A and B financings, a major Merck collaboration, and the acquisition of ReNAgade. From 2020 to 2024, he was also an Entrepreneur Partner at MPM Bioimpact. As a founding CSO of Intellia Therapeutics, he helped build the company, including IPO and follow-on financings, and helped advance the CRISPR platform into ex vivo therapeutics.
He holds a PhD from the University of Cambridge and completed fellowships at Harvard Medical School and McGill University.